Norwalk virus

(redirected from NLV)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms.

Norwalk virus:

see norovirusnorovirus
or Norwalk virus,
highly contagious viral disease caused by infection with an RNA virus of the genus Norovirus. The virus causes acute gastroenteritis, usually one to two days after infection; typical symptoms are abdominal pain and cramps, diarrhea,
..... Click the link for more information.
Mentioned in ?
References in periodicals archive ?
The argument discrediting the NLV methodology because it assumes a hypothetical concept as a construct of the valuation process can be said of any and all valuation processes; there are certain hypothetical concepts necessary for the appraisal process that are not conditions of an assignment.
In Italy, which has no surveillance system for nonbacterial gastroenteritis, the impact of NLV infection is unknown, and no previous outbreaks of confirmed NLV infection have been reported.
NLV is a mutual life insurance company domiciled in Vermont and licensed in all 50 states, with statutory admitted assets of $6 billion and statutory adjusted surplus was $489 million at June 30, 1998.
Zadno commented, "I am very pleased to join NLV Partners.
Only 5% of respondents listed NLV among the three most common causes of foodborne illness; this agent is estimated to cause 67% of all foodborne disease in the United States (1).
Investments: NLV maintains a high-quality investment portfolio with a high percentage of investments, 62%, as of Dec.
The ubiquitous nature and [ILLEGIBLE TEXT] viral agents make similar future outbreaks of NLV gastroenteritis a near [ILLEGIBLE TEXT] a valuable diagnostic tool in the identification of NLVs as the etiologic agent in [ILLEGIBLE TEXT]
In addition, we analyzed (by sequence analysis) the genetic variation of detected calicivirus strains and compared it with that of prototype GGI and GGII NLV strains.
NLV assumed to account for 11% of an estimated 2,800 fatal cases of viral gastroenteritis each year (100).
Additional involvement of the Aboriginal community in the management of the facility would continue as part of Aboriginal Participation Program signed with NLV.
The Series D financing was led by NLV Partners, and additional participants included new investor Kaiser Permanente Ventures and existing investors Clarus Ventures, Wellington Partners, Kuwait-based National Technology Enterprises Company, SPARK Ventures, DFJ Esprit, Oxford University and The Dow Chemical Company.